# Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP3A4 Inhibitor, Ketoconazole, or a CYP3A4 Inducer, Rifampin.

> **NCT01637636** · PHASE1 · COMPLETED · sponsor: **Vanda Pharmaceuticals** · enrollment: 48 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** tasimelteon
- **DRUG:** tasimelteon
- **DRUG:** Rifampin
- **DRUG:** Ketoconazole

## Key facts

- **NCT ID:** NCT01637636
- **Lead sponsor:** Vanda Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2014-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01637636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01637636, "Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP3A4 Inhibitor, Ketoconazole, or a CYP3A4 Inducer, Rifampin.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01637636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*